{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T20:56:20Z","timestamp":1790024180617,"version":"4.0.1"},"reference-count":61,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,8,31]],"date-time":"2022-08-31T00:00:00Z","timestamp":1661904000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81974001, 82170222"],"award-info":[{"award-number":["81974001, 82170222"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004608","name":"Natural Science Foundation of Jiangsu Province","doi-asserted-by":"publisher","award":["BK20211070"],"award-info":[{"award-number":["BK20211070"]}],"id":[{"id":"10.13039\/501100004608","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100018556","name":"Science and Technology Program of Suzhou","doi-asserted-by":"publisher","award":["LCZX202101"],"award-info":[{"award-number":["LCZX202101"]}],"id":[{"id":"10.13039\/501100018556","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013076","name":"National Major Science and Technology Projects of China","doi-asserted-by":"publisher","award":["2017ZX09304021"],"award-info":[{"award-number":["2017ZX09304021"]}],"id":[{"id":"10.13039\/501100013076","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["2019YFC0840604, 2017YFA0104502"],"award-info":[{"award-number":["2019YFC0840604, 2017YFA0104502"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012246","name":"Priority Academic Program Development of Jiangsu Higher Education Institutions","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100012246","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100018612","name":"Jiangsu Province's Key Provincial Talents Program","doi-asserted-by":"publisher","award":["BE2019670"],"award-info":[{"award-number":["BE2019670"]}],"id":[{"id":"10.13039\/501100018612","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005066","name":"Key Medical Subjects of Jiangsu Province","doi-asserted-by":"publisher","award":["YXZXA2016002"],"award-info":[{"award-number":["YXZXA2016002"]}],"id":[{"id":"10.13039\/501100005066","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Rituximab is used to eliminate B cells as a chimeric monoclonal antibody directed against CD20, a B-cell antigen expressed on B cells. To explore the impact of rituximab administered before transplantation, we implemented a retrospective, monocentric study and utilized real-world data collected at our center between January 2018 and December 2020, and then followed until December 2021. Based on whether a dose of 375mg\/m<jats:sup>2<\/jats:sup> rituximab was used at least once within two weeks before transplantation, patients undergoing allo-HSCT were classified into two groups: rituximab (N=176) and non-rituximab (N=344) group. Amongst all the patients, the application of rituximab decreased EBV reactivation (P&amp;lt;0.01) and rituximab was an independent factor in the prevention of EBV reactivation by both univariate and multivariate analyses (HR 0.56, 95%CI 0.33-0.97, P=0.04). In AML patients, there were significant differences in the cumulative incidence of aGVHD between the two groups (P=0.04). Our data showed that rituximab was association with a decreased incidence of aGVHD in AML patients according to both univariate and multivariate analyses. There was no difference between the two groups in other sets of populations. Thus, our study indicated that rituximab administered before transplantation may help prevent EBV reactivation in all allo-HSCT patients, as well as prevent aGVHD in AML patients after allo-HSCT.<\/jats:p>","DOI":"10.3389\/fimmu.2022.967026","type":"journal-article","created":{"date-parts":[[2022,8,31]],"date-time":"2022-08-31T08:09:48Z","timestamp":1661933388000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":13,"title":["The impact of Rituximab administered before transplantation in patients undergoing allogeneic hematopoietic stem cell transplantation: A real-world study"],"prefix":"10.3389","volume":"13","author":[{"given":"Xiya","family":"Wei","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiyu","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruoyu","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huiyu","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heqing","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuqi","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ling","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiyuan","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zaixiang","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Depei","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaojin","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,8,31]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa032534","article-title":"Efficacy of b-cell-targeted therapy with rituximab in patients with rheumatoid arthritis","volume":"350","author":"Edwards","year":"2004","journal-title":"N Engl J Med"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-6143.2006.01288.x","article-title":"Rituximab, an anti-cd20 monoclonal antibody: history and mechanism of action","volume":"6","author":"Pescovitz","year":"2006","journal-title":"Am J Transplant"},{"key":"B3","doi-asserted-by":"publisher","first-page":"794","DOI":"10.1097\/TP.0000000000000362","article-title":"A systematic review of the use of rituximab for desensitization in renal transplantation","volume":"98","author":"Macklin","year":"2014","journal-title":"Transplantation"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2009.07.004","article-title":"Clinical applications of rituximab in allogeneic stem cell transplantation: anti-tumor and immunomodulatory effects","volume":"35","author":"Ratanatharathorn","year":"2009","journal-title":"Cancer Treat Rev"},{"key":"B5","doi-asserted-by":"publisher","first-page":"S3","DOI":"10.1097\/00001813-200211002-00002","article-title":"Mechanism of action of rituximab","author":"Cerny","year":"2002","journal-title":"Anticancer Drugs"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1126\/science.aaz9356","article-title":"Structure of CD20 in complex with the therapeutic monoclonal antibody rituximab","volume":"367","author":"Roug\u00e9","year":"2020","journal-title":"Science"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2017.01245","article-title":"Therapeutic antibodies: What have we learnt from targeting CD20 and where are we going","volume":"8","author":"Marshall","year":"2017","journal-title":"Front Immunol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-06-2031","article-title":"Antibody specificity controls in vivo effector mechanisms of anti-CD20 reagents","volume":"103","author":"Cragg","year":"2004","journal-title":"Blood"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-017-0612-x","article-title":"Rituximab in b-cell hematologic malignancies: A review of 20 years of clinical experience","volume":"34","author":"Salles","year":"2017","journal-title":"Adv Ther"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1038\/sj.onc.1208349","article-title":"Cellular and molecular signal transduction pathways modulated by rituximab (rituxan, anti-CD20 mAb) in non-hodgkin's lymphoma: implications in chemosensitization and therapeutic intervention","volume":"24","author":"Jazirehi","year":"2005","journal-title":"Oncogene"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1080\/17843286.2018.1521904","article-title":"Rituximab in systemic autoimmune rheumatic diseases: indications and practical use","volume":"74","author":"Berghen","year":"2019","journal-title":"Acta Clin Belg"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1007\/s40257-019-00497-9","article-title":"Rituximab: A review in pemphigus vulgaris","volume":"21","author":"Frampton","year":"2020","journal-title":"Am J Clin Dermatol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1002\/mus.25597","article-title":"Rituximab treatment of myasthenia gravis: A systematic review","volume":"56","author":"Tandan","year":"2017","journal-title":"Muscle Nerve"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.08140910","article-title":"Desensitization protocols and their outcome","volume":"6","author":"Marfo","year":"2011","journal-title":"Clin J Am Soc Nephrol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1097\/TP.0b013e31827be3c1","article-title":"Rituximab prevents an anamnestic response in patients with cryptic sensitization to HLA","volume":"95","author":"Zachary","year":"2013","journal-title":"Transplantation"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.4103\/0971-4065.177207","article-title":"Rituximab in the treatment of refractory late acute antibody-mediated rejection: Our initial experience","volume":"26","author":"Surendra","year":"2016","journal-title":"Indian J Nephrol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1111\/ajt.14520","article-title":"Treatment of chronic antibody mediated rejection with intravenous immunoglobulins and rituximab: A multicenter, prospective, randomized, double-blind clinical trial","volume":"18","author":"Moreso","year":"2018","journal-title":"Am J Transplant"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1517\/14712598.2010.485982","article-title":"Rituximab in hematopoietic cell transplantation","volume":"10","author":"Arai","year":"2010","journal-title":"Expert Opin Biol Ther"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1586\/1744666X.2013.824667","article-title":"Impact of donor-specific antibodies in reconstructive transplantation","volume":"9","author":"Leto Barone","year":"2013","journal-title":"Expert Rev Clin Immunol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2013.04.016","article-title":"Monoclonal antibodies in conditioning regimens for hematopoietic cell transplantation","volume":"19","author":"Kharfan-Dabaja","year":"2013","journal-title":"Biol Blood Marrow Transpl"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1177\/1078155220948596","article-title":"Rituximab desensitization in pediatric acute lymphoblastic leukemia with severe anaphylaxis","volume":"27","author":"V Villarreal-Gonz\u00e1lez","year":"2020","journal-title":"J Oncol Pharm Pract"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2021004862","article-title":"Treatment of allosensitized patients receiving allogeneic transplantation","volume":"5","author":"Ciurea","year":"2021","journal-title":"Blood Adv"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1111\/petr.14113","article-title":"Use of rituximab for persistent EBV DNAemia, and its effect on donor-specific antibody development in pediatric renal transplant recipients: A case series","volume":"25","author":"Puliyanda","year":"2021","journal-title":"Pediatr Transplant"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2009.02.005","article-title":"Rituximab treatment before reduced-intensity conditioning transplantation associates with a decreased incidence of extensive chronic GVHD","volume":"15","author":"van Dorp","year":"2009","journal-title":"Biol Blood Marrow Transpl"},{"key":"B25","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.jneuroim.2017.05.021","article-title":"Responsiveness to low-dose rituximab in refractory generalized myasthenia gravis","volume":"311","author":"Jing","year":"2017","journal-title":"J Neuroimmunol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1016\/j.exphem.2011.06.006","article-title":"Prior rituximab administration is associated with reduced rate of acute GVHD after in vivo T-cell depleted transplantation in lymphoma patients","volume":"39","author":"Crocchiolo","year":"2011","journal-title":"Exp Hematol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2011.28","article-title":"In vivo b-cell depletion with rituximab for alternative donor hemopoietic SCT","volume":"47","author":"Dominietto","year":"2012","journal-title":"Bone Marrow Transplant"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1111\/j.1399-3046.2011.01634.x","article-title":"Incidence, kinetics, and risk factors of Epstein-Barr virus viremia in pediatric patients after allogeneic stem cell transplantation","volume":"16","author":"Bordon","year":"2012","journal-title":"Pediatr Transpl"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1038\/s41409-017-0062-8","article-title":"The European society for blood and marrow transplantation (EBMT) consensus guidelines for the detection and treatment of donor-specific anti-HLA antibodies (DSA) in haploidentical hematopoietic cell transplantation","volume":"53","author":"Ciurea","year":"2018","journal-title":"Bone Marrow Transplant"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1002\/jcla.23261","article-title":"Combination treatment of rituximab and donor platelets infusion to reduce donor-specific anti-HLA antibodies for stem cells engraftment in haploidentical transplantation","volume":"34","author":"Zhang","year":"2020","journal-title":"J Clin Lab Anal"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtct.2022.05.017","article-title":"Relationship of oropharyngeal colonization microorganisms to clinical outcomes within 100 days after allogeneic hematopoietic stem cell transplantation","volume":"28","author":"Jianrong","year":"2022","journal-title":"Transplant Cell Ther"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1705425","article-title":"Allogeneic hematopoietic stem cell transplantation after rituximab-containing myeloablative preparative regimen for acute lymphoblastic leukemia","volume":"38","author":"Kebriaei","year":"2006","journal-title":"Bone Marrow Transplant"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-01-136242","article-title":"Eight-year experience with allogeneic stem cell transplantation for relapsed follicular lymphoma after nonmyeloablative conditioning with fludarabine, cyclophosphamide, and rituximab","volume":"111","author":"Khouri","year":"2008","journal-title":"Blood"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2013.84","article-title":"Reduced PTLD-related mortality in patients experiencing EBV infection following allo-SCT after the introduction of a protocol incorporating pre-emptive rituximab","volume":"48","author":"van der Velden","year":"2013","journal-title":"Bone Marrow Transpl"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1038\/s41409-019-0699-6","article-title":"Pre-emptive rituximab treatment for Epstein-Barr virus reactivation after allogeneic hematopoietic stem cell transplantation is a worthwhile strategy in high-risk recipients: a comparative study for immune recovery and clinical outcomes","volume":"55","author":"Stocker","year":"2020","journal-title":"Bone Marrow Transplant"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1097\/TP.0b013e3182664042","article-title":"Increased infection rate after preemptive rituximab treatment for Epstein-Barr virus reactivation after allogeneic hematopoietic stem-cell transplantation","volume":"94","author":"Petropoulou","year":"2012","journal-title":"Transplantation"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2010.05.004","article-title":"Rituximab administration within 6 months of T cell-depleted allogeneic SCT is associated with prolonged life-threatening cytopenias","volume":"16","author":"McIver","year":"2010","journal-title":"Biol Blood Marrow Transplant"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.14664","article-title":"The effect of rituximab on anti-platelet autoantibody levels in patients with immune thrombocytopenia","volume":"178","author":"Arnold","year":"2017","journal-title":"Br J Haematol"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2019.218883","article-title":"Rituximab in the treatment of immune thrombocytopenia: what is the role of this agent in 2019","volume":"104","author":"Lucchini","year":"2019","journal-title":"Haematologica"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019000928","article-title":"Primary immunodeficiencies reveal the molecular requirements for effective host defense against EBV infection","volume":"135","author":"Tangye","year":"2020","journal-title":"Blood"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-019-03603-3","article-title":"Incidence, risk factors, and clinical significance of Epstein-Barr virus reactivation in myelodysplastic syndrome after allogeneic haematopoietic stem cell transplantation","volume":"98","author":"Wang","year":"2019","journal-title":"Ann Hematol"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1038\/s41409-019-0627-9","article-title":"Prognostic impact of EBV serostatus in patients with lymphomas or chronic malignancies undergoing allogeneic HCT","volume":"54","author":"Styczynski","year":"2019","journal-title":"Bone Marrow Transplant"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1111\/tid.12618","article-title":"Dynamics of Epstein-Barr viral load after hematopoietic stem cell transplantation and effect of preemptive rituximab therapy","volume":"18","author":"Raberahona","year":"2016","journal-title":"Transpl Infect Dis"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1705445","article-title":"Haploidentical hematopoietic stem cell transplantation without in vitro T-cell depletion for the treatment of hematological malignancies","volume":"38","author":"Huang","year":"2006","journal-title":"Bone Marrow Transplant"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2012.117","article-title":"Incidence and risk factors of EBV reactivation after unrelated cord blood transplantation: a eurocord and societe francaise de greffe de moelle-therapie cellulaire collaborative study","volume":"48","author":"Dumas","year":"2013","journal-title":"Bone Marrow Transplant"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2016.19","article-title":"Greatly reduced risk of EBV reactivation in rituximab-experienced recipients of alemtuzumab-conditioned allogeneic HSCT","volume":"51","author":"Burns","year":"2016","journal-title":"Bone Marrow Transpl"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2018.1543877","article-title":"Prophylactic rituximab prevents EBV PTLD in haplo-cord transplant recipients at high risk","volume":"60","author":"Van Besien","year":"2019","journal-title":"Leuk Lymphoma"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1038\/s41409-018-0124-6","article-title":"Outcomes of a novel rituximab-based non-myeloablative conditioning regimen for hematopoietic cell transplantation in severe aplastic anemia","volume":"53","author":"Gatwood","year":"2018","journal-title":"Bone Marrow Transplant"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-09-045625","article-title":"Distinct EBV and CMV reactivation patterns following antibody-based immunosuppressive regimens in patients with severe aplastic anemia","volume":"109","author":"Scheinberg","year":"2007","journal-title":"Blood"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1016\/j.retram.2019.03.001","article-title":"Low dose rituximab for pre-emptive treatment of Epstein Barr virus reactivation after allogenic hematopoietic stem cell transplantation","volume":"67","author":"Delapierre","year":"2019","journal-title":"Curr Res Transl Med"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1111\/ejh.13308","article-title":"Reactivation and dynamics of cytomegalovirus and Epstein-Barr virus after rabbit antithymocyte globulin and cyclosporine for aplastic anemia","volume":"103","author":"Park","year":"2019","journal-title":"Eur J Haematol"},{"key":"B52","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1182\/blood.2019000952","article-title":"Cytokines and Co-stimulation in acute graft-versus-Host disease","volume":"136","author":"Hill","year":"2020","journal-title":"Blood"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1080\/2162402x.2015.1016707","article-title":"Deficient regulatory b cells in human chronic graft-versus-host disease","volume":"4","author":"De Masson","year":"2015","journal-title":"OncoImmunology"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1097\/01.tp.0000282786.58754.2b","article-title":"Rituximab removes intrarenal b cell clusters in patients with renal vascular allograft rejection","volume":"84","author":"Steinmetz","year":"2007","journal-title":"Transplantation"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1038\/s41409-020-0788-6","article-title":"Outcomes of conditioning with rabbit antithymocyte globulin and rituximab in haploidentical haematopoietic stem cell transplantation in patients with severe aplastic anaemia","volume":"55","author":"Liu","year":"2020","journal-title":"Bone Marrow Transplant"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1177\/1078155216637216","article-title":"Risk of graft-versus-host disease with rituximab-containing conditioning regimens in allogeneic hematopoietic stem cell transplant","volume":"23","author":"Marini","year":"2017","journal-title":"J Oncol Pharm Pract"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1007\/s12185-011-0855-2","article-title":"Rituximab for prevention and treatment of graft-versus-host disease","volume":"93","author":"Kharfan-Dabaja","year":"2011","journal-title":"Int J Hematol"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.13311","article-title":"B-cell involvement in chronic graft-versus-host disease","volume":"93","author":"Kapur","year":"2008","journal-title":"Haematologica"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-11-784017","article-title":"B-cell targeting in chronic graft-versus-host disease","volume":"131","author":"Zeiser","year":"2018","journal-title":"Blood"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2008.385","article-title":"Delay in b-lymphocyte recovery and function following rituximab for EBV-associated lymphoproliferative disease early post-allogeneic hematopoietic SCT","volume":"43","author":"Masjosthusmann","year":"2009","journal-title":"Bone Marrow Transplant"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-08-104745","article-title":"Reduced-toxicity conditioning with fludarabine, BCNU, and melphalan in allogeneic hematopoietic cell transplantation: particular activity against advanced hematologic malignancies","volume":"112","author":"Marks","year":"2008","journal-title":"Blood"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.967026\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,31]],"date-time":"2022-08-31T08:09:56Z","timestamp":1661933396000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.967026\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,31]]},"references-count":61,"alternative-id":["10.3389\/fimmu.2022.967026"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2022.967026","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,31]]},"article-number":"967026"}}